AMLX Stock Analysis: Buy, Sell, or Hold?
AMLX - Amylyx Pharmaceuticals, Inc. Common Stock
$17.41
-0.36 (-2.03%)
▼
5d:
-3.12%
30d:
+29.35%
90d:
+6.42%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When AMLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called AMLX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AMLX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AMLX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AMLX is currently trading at $17.41, which is considered slightly high relative to its 30-day fair value range of $14.42 to $18.09.
Technical Outlook: Technically, AMLX is in a strong uptrend. The price is currently testing key support at $16.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $24.40 (+40.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AMLX is in a strong uptrend. The price is currently testing key support at $16.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $24.40 (+40.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$14.42 -
$18.09
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.8%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.1% below Wall St target ($24.40)
Trading Range Analysis
30-Day Trading Range
$14.42 -
$18.09
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$16.96
Resistance Level
$19.15
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.75
Wall Street Target
$24.40
(+40.1%)
Revenue Growth (YoY)
-99.6%
Share & Embed Analysis
Last updated: July 13, 2026 10:25 PM ET
Data refreshes hourly during market hours. Next update: 11:25 PM
Data refreshes hourly during market hours. Next update: 11:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Joshua B Cohen
SELL
1974 shares
2026-01-16
Justin B Klee
SELL
1995 shares
2026-01-16
Joshua B Cohen
SELL
136193 shares
2026-01-15
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
Advanced AMLX Option Strategies
Professional options setups generated by AI based on today's AMLX price and gamma walls.
